AMPHETAMINE INDUCED 11C RACLOPRIDE DISPLACEMENT IN MOOD DISORDERS

安非他明引起心境障碍中的 11C 雷氯必利置换

• 批准号: 6304640
• 负责人: WAYNE C DREVETS
• 金额: $ 0.3万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304640
• 关键词: amphetamines; clinical research; dopamine; drug interactions; human subject; major depression; mood disorders; neurochemistry; pharmacokinetics; positron emission tomography; raclopride

The objective of this study is to assess central dopaminergic function in major depressive disorder (MDD). PET measures of [11C]-raclopride uptake will be acquired at baseline, after amphetamine (AMPH)-induced dopamine (DA) release and following a-methyl-para-tyrosine (aMPT) induced DA depletion in control and depressed samples. The 11C-raclopride uptake in these conditions will provide measures of the baseline dopamine D2/D3 receptor binding, the baseline occupancy of these receptors by endogenous DA and the amount of DA released following AMPH administration in each subject sample. These measures will be compared between depressives and controls to test the hypothesis that MDD is associated with a reduction in ventral striatal DA concentrations.

本研究的目的是评估重度抑郁症（MDD）的中枢多巴胺能功能。 在对照和抑郁样品中，在安非他明 (AMPH) 诱导的多巴胺 (DA) 释放后以及 a-甲基对酪氨酸 (aMPT) 诱导的 DA 消耗后，将在基线时获取 [11C]-雷氯必利摄取的 PET 测量。 这些条件下的 11C-雷氯必利摄取将提供基线多巴胺 D2/D3 受体结合、内源 DA 对这些受体的基线占用以及每个受试者样品中 AMPH 给药后释放的 DA 量的测量。 这些措施将在抑郁症患者和对照组之间进行比较，以检验 MDD 与腹侧纹状体 DA 浓度降低相关的假设。